Overview

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
0
Participant gender:
Female
Summary
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance. Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour. The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Cancer Centre, Singapore
Collaborator:
National Medical Research Council (NMRC), Singapore
Treatments:
Bexarotene
Capecitabine
Criteria
Inclusion Criteria:

- Patients with histologically or cytologically proven metastatic TNBC

- Patients whose TNBC has progressed after prior taxane therapy in the metastatic
setting, and have not received Capecitabine or 5-fluorouracil

- Females aged 21 years and older

- ECOG performance status 0 or 1

- Life expectancy greater than three months

- Patients have normal organ and marrow function

- Site(s) of disease amenable to serial bedside biopsies before, during and after study
treatment

Exclusion Criteria:

- Previous palliative radiotherapy to potentially biopsy-able lesion

- Active symptomatic central nervous system (CNS) metastases

- Spinal cord compression not definitively treated with surgery and/or radiation

- Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent
drainage procedures